A Phase 1 interventional study of rabeprazole and rabeprazole in Healthy, sponsored by Eisai Co., Ltd.. Completed. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-13.
Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the pharmacokinetics of rabeprazole under fasting condition.
The purpose of this study is to assess bioequivalence after single administration of the following 4 types of formulation: normal 10 mg rabeprazole tablet rabeprazole, and Type 1, Type 2, and Type 3 granule formulation containing rabeprazole 10 mg.
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with homozygous or heterozygous extensive metabolizers of cytochrome P4502C19.
Exclusion criteria:
Subjects with allergy
Drug: rabeprazole
Drug: rabeprazole
Drug: rabeprazole
Drug: rabeprazole
10 mg normal tablet
Type 1 granule containing rabeprazole 10 mg
Type 2 granule containing rabeprazole 10 mg
Type 3 granule containing rabeprazole 10 mg
The following pharmacokinetic parameters are calculated: maximum drug concentration (Cmax) in plasma; area under the plasma concentration time curve (AUC)
Time frame: One day
Vital signs, clinical laboratory screens of blood and urine, adverse event monitoring, adverse drug reaction monitoring
Time frame: 13 days
No study locations are listed for this record.
The record gives a start of Apr 2010, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole